by The Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
The disease causes scarring and strictures in the bile ducts which can lead to complications like cirrhosis, inflammation of the pancreas, and liver cancer. Current treatments are aimed at reducing symptoms, slowing disease progression, and preventing complications. Medical therapies include medications like ursodeoxycholic acid and combination therapies involving anti-fibrotic, anti-inflammatory and immunomodulatory drugs. Liver transplant may be considered for advanced stage disease.
Market Dynamics:
Increasing research and development of promising combination therapies is a key driver fueling the growth of the primary sclerosing cholangitis market. Major companies are conducting clinical trials on combinations of ursodeoxycholic acid with other molecules that reduce inflammation and fibrosis. For instance, clinical trial NCT03344886 is evaluating a combination of obeticholic acid and bezafibrate for PSC. Similarly, trial NCT03745610 is assessing efficacy of seladelpar in combination with UDCA for treating PSC. Rising adaptation of combination therapies as first-line treatment is expected to boost the market growth. Additionally, growing clinical trial activities, improving awareness about the disease and increasing approval of new drugs are some other important factors anticipated to positively impact the market during the forecast period.
Segment Analysis
Primary Sclerosing Cholangitis market Growth is segmented on the basis of treatment into ursodeoxycholic acid, antibiotics, obeticholic acid, and others. Amongst these, the antibiotics segment currently dominates the market due to rising cases of bacterial infections associated with primary sclerosing cholangitis. Antibiotics help treat infections and reduce symptoms in patients with primary sclerosing cholangitis.
PEST Analysis
Political: Government regulations to support advancements in treatment therapies for rare diseases including primary sclerosing cholangitis drive the market growth.
Economic: Rising healthcare expenditures along with increasing affordability fuel the primary sclerosing cholangitis market size.
Social: Growing public-private collaborations to create awareness about rare diseases and their treatment augment the market expansion.
Technological: Developments in gene therapy and biomarkers help achieve accurate diagnosis and offer personalized treatment protocols.
Key Takeaways
The global primary sclerosing cholangitis market is expected to witness high growth, exhibiting CAGR of 7.6% over the forecast period, due to increasing investment in R&D of advanced treatment therapies.
Regional analysis: North America dominates the primary sclerosing cholangitis market and is expected to continue its dominance over the forecast period. This is attributed to growing initiatives by organizations for treatment access and increasing healthcare expenditures in the region.
Key players operating in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd. Key players are majorly focused on developing advanced treatment therapies for better outcomes in patients.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
